Compare Amgen, Inc. (AMGN) vs Motorola Solutions Inc (MSI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Motorola Solutions Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Motorola Solutions Inc trades at $424.88 (market cap $70.20B). The key difference: Amgen, Inc. is far larger — about 2.8× Motorola Solutions Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | MSI | |
|---|---|---|
Market Cap | $196.12B | $70.20B |
Sector | Health | Technology |
52-Week High | $388.16 | $490.30 |
52-Week Low | $271.18 | $363.83 |
Enterprise Value | $241.41B | $78.90B |
Dividend Yield | 2.77% | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Motorola Solutions (MSI) trades at $422.88, up 1.36% with a bullish technical outlook. The stock shows strong fundamentals with Q1 2026 EPS beating estimates at $3.37 versus $3.24 expected, and a robust net income margin of 17.61%. Recent news highlights AI expansion in public safety, including the $1.5 billion acquisition of D-Fend Solutions, enhancing its competitive edge in counter-drone technology.
Outlook remains positive with a consensus price target of $512.33, indicating 21% upside. Risks include high valuation multiples like a P/E of 34.1 and increased debt from acquisitions. The company's focus on mission-critical AI and a $15.7 billion backlog supports growth, but investors should monitor integration execution and macroeconomic pressures on public spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →
